Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voglibose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM known ✓ | O43451 | 18/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 1.00 |
| ▸ | SI known ✓ | P14410 | 17/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voglibose SCHEMBL27565869 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL5882 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL17396338 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL14992258 | 1.00 | MGAM (1.00) | MGAMGAALMNASI | |
| Voglibose SCHEMBL6245153 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL5028621 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL11286105 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL3244186 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL10670275 | 0.98 | MGAM (0.97) | MGAMGAALMNASI | |
| Voglibose SCHEMBL1116195 | 0.98 | MGAM (0.97) | MGAMGAALMNASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| EP-2213289-A1 | Combination treatment for diabetes mellitus | Nycomed GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | MGAM 530/4885GAA 1043/4885SI 1011/4885 |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | MGAM 256/4885GAA 635/4885SI 755/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | MGAM 798/4885GAA 1177/4885SI 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.